The Link Between Osteoporosis Medications (Bisphosphonates) and Jaw Health

Introduction

If you or someone you care for has been prescribed medication for osteoporosis, you may have come across references to potential effects on dental health. Many patients search online after hearing their dentist ask about medications during a routine appointment, or after being told that a dental procedure may need additional consideration due to their prescription.

Bisphosphonates are a widely used group of medications prescribed to help strengthen bones and reduce the risk of fractures in people with osteoporosis. While they play an important role in managing bone health, there is a recognised link between long-term bisphosphonate use and a rare but significant jaw condition known as medication-related osteonecrosis of the jaw (MRONJ).

This article aims to explain clearly what bisphosphonates are, how they may affect the jaw, what signs patients should be aware of, and why open communication with your dental team is an important part of safe, informed dental care. Understanding this connection can help patients make well-informed decisions about their oral health alongside their wider medical treatment.

---

Featured Snippet: What Is the Link Between Bisphosphonates and Jaw Health?

Bisphosphonates, commonly prescribed for osteoporosis, can reduce the jaw bone's ability to heal following dental procedures or injury. In rare cases, this may lead to a condition called medication-related osteonecrosis of the jaw (MRONJ), where bone tissue fails to heal properly. Early dental assessment and clear communication with your dental team are important for safe care.

---

What Are Bisphosphonates and Why Are They Prescribed?

Bisphosphonates are a class of medicines widely used to treat conditions that weaken bones, including osteoporosis, Paget's disease of bone, and certain bone complications associated with cancer treatment. They work by slowing down the natural process by which the body breaks down old bone tissue, helping to maintain or increase bone density over time.

Common examples of bisphosphonates prescribed in the UK include alendronic acid (alendronate), risedronate, ibandronate, and zoledronic acid. Oral forms are typically taken weekly or monthly as tablets, while intravenous (IV) forms are administered in a clinical setting and are generally associated with higher doses used in cancer-related bone disease.

These medications are often prescribed by GPs or specialist physicians and are considered an effective and well-established treatment for reducing fracture risk in people with low bone density. Many millions of people take bisphosphonates worldwide without experiencing any dental complications. However, because these medications affect bone metabolism, it is important for patients to inform their dental team about their prescription, regardless of how long they have been taking the medication.

---

How Do Bisphosphonates Affect the Jaw? The Clinical Explanation

To understand why bisphosphonates can affect jaw health, it helps to understand a little about how bone tissue normally works. Bone is a living tissue that constantly renews itself through a process involving two types of cells: osteoblasts, which build new bone, and osteoclasts, which break down old or damaged bone. This cycle of bone remodelling keeps the skeleton healthy and allows bone to repair itself after minor damage.

Bisphosphonates work by inhibiting osteoclast activity — essentially slowing down the breakdown of bone. In most parts of the skeleton, this is beneficial, as it helps preserve bone density. However, the jaw is a unique environment. It is regularly exposed to mechanical stress from chewing, is in close contact with the oral environment (including bacteria), and may be subjected to dental procedures such as extractions, implants, or periodontal treatment.

When the jaw's natural remodelling process is impaired, the bone's capacity to heal following injury or dental procedures may be reduced. In rare cases, this can result in MRONJ — a condition where a portion of jaw bone fails to heal and may become exposed through the gum tissue. The risk is considered significantly higher with high-dose intravenous bisphosphonates used in cancer treatment compared to the lower oral doses typically prescribed for osteoporosis.

---

What Is Medication-Related Osteonecrosis of the Jaw (MRONJ)?

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious condition in which bone tissue in the jaw does not heal properly after being exposed to certain medications that affect bone metabolism. The term "osteonecrosis" refers to the death of bone tissue due to a disrupted blood or healing supply.

MRONJ is not limited to bisphosphonates alone — it has also been associated with other bone-modifying agents such as denosumab and certain targeted cancer therapies. However, bisphosphonates remain the most commonly implicated class of medication, particularly high-dose IV preparations used in oncology settings.

For patients taking oral bisphosphonates for osteoporosis, the overall risk of developing MRONJ remains low. Studies suggest the estimated incidence in this group ranges from approximately 0.01% to 0.04% per year of exposure, though risk may increase with longer duration of use. The condition most commonly occurs following dental extractions or other invasive dental procedures, though it may occasionally arise spontaneously.

It is important to note that a diagnosis of MRONJ can only be made following a thorough clinical and radiographic examination by a qualified dental professional. This article does not constitute a diagnosis, and patients with concerns should always seek professional assessment.

---

Signs and Symptoms Patients Should Be Aware Of

Understanding what to look out for can help patients seek timely professional advice. It is important to emphasise that many of the signs below may have other entirely unrelated causes, and the presence of any symptom does not confirm a diagnosis of MRONJ. Only a dental professional can assess symptoms properly during an examination.

Signs that may warrant a dental review include:

• Exposed bone in the mouth — an area of pale or yellowish bone visible through the gum tissue that does not appear to be healing
• Pain or discomfort in the jaw — particularly in the lower jaw, that has persisted for several weeks
• Swelling or redness in the gum or jaw area — that does not respond to standard treatment
• Numbness or a heavy feeling in the jaw — sometimes described as a sensation similar to dental anaesthesia that lingers
• Loose teeth — without an obvious cause such as advanced gum disease
• Delayed healing following a dental extraction or procedure

If you are taking bisphosphonates or other bone-modifying medications and notice any of the above, it is advisable to contact your dental team for an assessment. Early professional evaluation is always recommended rather than waiting to see if symptoms resolve on their own.

---

The Importance of Telling Your Dentist About Your Medications

One of the most important steps any patient can take when managing both their general and oral health is to ensure their dental team is fully informed about all current medications — including bisphosphonates.

This is not simply a formality. Knowing a patient's full medication history allows the dental team to plan care appropriately, consider the timing of certain procedures, and take additional precautions where needed. For patients on oral bisphosphonates for osteoporosis, routine dental treatment — including hygiene appointments, fillings, and crown work — is generally considered safe. However, for procedures involving the bone, such as extractions or dental implants, your dentist may wish to seek guidance from your prescribing physician or consider a referral to a specialist oral surgeon.

If you are due to begin bisphosphonate therapy, it is worth scheduling a comprehensive dental assessment beforehand if possible. This allows any existing dental problems — such as failing teeth or gum disease — to be addressed before starting medication, potentially reducing future risk.

Regular dental hygiene appointments are particularly valuable for patients on bisphosphonates, as maintaining excellent gum and bone health can help reduce the likelihood of needing invasive dental treatment in the future. You can find out more about the role of professional dental hygiene visits in supporting your overall oral health on our dental hygiene services page.

---

When Professional Dental Assessment May Be Needed

There are several situations in which patients taking bisphosphonates or other bone-modifying therapies should seek professional dental assessment:

• Before starting bisphosphonate treatment — a pre-treatment dental check-up is often recommended to address any existing dental issues
• Before invasive dental procedures — such as tooth extractions, implant placement, or periodontal surgery, your dentist may wish to discuss your medication history and seek specialist input
• If you notice any unusual symptoms — such as those described in the previous section, including exposed bone, persistent pain, or delayed healing
• At regular intervals — routine dental check-ups and hygiene appointments allow your dental team to monitor your oral health and identify any concerns early

Dental symptoms and treatment options should always be assessed individually during a clinical examination. If you are ever unsure whether your symptoms are dental-related, contacting your dental practice directly for guidance is always the right step.

Watch our educational video to learn more about the role of dental hygienists in supporting your preventative care:

---

Dental Procedures and Risk Management for Bisphosphonate Patients

For patients on oral bisphosphonates, the vast majority of routine dental treatments can proceed safely. The key principle in dental care for these patients is informed, cautious planning — particularly when any bone-level intervention is being considered.

Current clinical guidelines from bodies including the British Association of Oral and Maxillofacial Surgeons (BAOMS) suggest that patients on low-dose oral bisphosphonates for osteoporosis can generally undergo dental extractions with appropriate precautions, such as minimising trauma, ensuring good infection control, and promoting socket healing. A decision to pause or alter bisphosphonate therapy before or after a dental procedure — sometimes referred to as a "drug holiday" — may be discussed between the patient's dentist and prescribing physician in certain circumstances, though this is an individualised clinical decision.

For patients receiving high-dose intravenous bisphosphonates (typically as part of cancer treatment), the risk profile is considerably higher, and a specialist multidisciplinary approach is usually recommended before any invasive dental procedure.

It is always the responsibility of your dental professional to review your individual circumstances and formulate an appropriate care plan. No general guidance replaces a face-to-face clinical assessment.

---

Prevention and Maintaining Good Oral Health on Bisphosphonates

While MRONJ is rare, there are practical and evidence-supported steps that patients taking bisphosphonates can take to protect their oral health and potentially reduce their risk of dental complications:

• Attend regular dental check-ups — ideally every six to twelve months, as recommended by your dental team, so that any developing issues can be identified and managed early
• Maintain excellent oral hygiene at home — brushing twice daily with fluoride toothpaste, cleaning between teeth daily with interdental brushes or floss, and using any additional aids recommended by your hygienist
• Attend regular professional hygiene appointments — a dental hygienist can remove plaque and tartar build-up that home brushing cannot reach, reducing your risk of gum disease and the need for more invasive treatment
• Address dental problems promptly — do not delay treatment for tooth decay, failing teeth, or gum disease, as untreated problems may eventually require more invasive intervention
• Inform all dental team members about your medication — including at every appointment, as your medication or dosage may change over time
• Avoid smoking — smoking is an established risk factor for impaired healing and gum disease, and may compound risk in bisphosphonate patients
• Maintain a well-balanced diet — good nutrition supports overall bone and tissue health

If you would like to find out more about maintaining your gum health through professional preventative care, explore our information on gum disease prevention and hygiene treatment.

---

Conclusion

The relationship between bisphosphonate medications and jaw health is an important area of understanding for patients managing osteoporosis and other bone conditions. While these medications provide significant benefits for bone density and fracture prevention, a small but real risk exists regarding their impact on the jaw's ability to heal — particularly following invasive dental procedures.

The good news is that for most patients taking oral bisphosphonates for osteoporosis, the risk of serious jaw complications remains low, and routine dental care can continue safely with appropriate communication and planning. The most important action any patient can take is to keep their dental team fully informed about their medications, attend regular check-ups and hygiene appointments, and seek professional advice promptly if any concerning symptoms arise.

Dental symptoms and treatment options should always be assessed individually during a clinical examination. If you have questions about your oral health in relation to bisphosphonate treatment, we encourage you to speak directly with your dental team, who can provide guidance tailored to your individual circumstances.

---